Optimizing Outcomes in the Management of GIST

Introduction Gastrointestinal Stromal Tumor (GIST)

KIT Mutations in GIST

Challenges of Treating Advanced Disease

Case Study: Advanced GIST

Resistance to Imatinib

Mutational Testing

Imatinib for GIST

MetaGIST

Imatinib AEs (≥ 30% of Patients in Clinical Trials)

Combined Surgical and Molecular Therapy

Managing Imatinib Resistance

Sunitinib Phase 3 Trial

Correlation of Mutational Status With Clinical Benefit in GIST Treated With Sunitinib

Sunitinib AEs (≥ 20% of Patients in Clinical Trials)

Management of Select AEs

Continuous Daily Dosing of Sunitinib

Tools for Preventing and Managing AEs

Supporting Adherence

Regorafenib

GRID Trial Regorafenib

Regorafenib AEs (≥ 20% of Patients in Clinical Trials)

Secondary Mutations of Exon 17 and Response to Regorafenib

Managing Patients on Oral Medications

Fourth-Line Options

Why Has the Patient Progressed After Third-Line Options?

Ongoing Clinical Trials

Concluding Remarks

Abbreviations

Abbreviations (cont)